Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,144.77 +13.27 (+1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
These stocks have generally delivered competitive returns. 
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Via Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
Via Benzinga
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Bagger Stocks: Can You Find One?
Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors. 
Via Talk Markets
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment. 
Via Benzinga
Exposures Product Safety
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
Via Benzinga
Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Alphabet Turns Twenty
Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13. 
Via Talk Markets
7 Stocks That Usually Benefit From a Recession
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession. 
Via InvestorPlace
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility. 
Via InvestorPlace
3 Biotech Stocks With Promising Drug Pipelines: August 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
Exposures Product Safety
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Healthcare Stocks Positioned for Possible Market Outperformance
While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market. 
Via InvestorPlace
Is Regeneron Pharmaceuticals Due for a Stock Split?
Would a stock split help lead Regeneron Pharmaceuticals shares higher? 
Via The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%... 
Via Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron. 
Via Investor's Business Daily
Regeneron Reports Second Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.